Trials / Active Not Recruiting
Active Not RecruitingNCT06220604
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 731 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-77242113 | JNJ-77242113 will be administered orally. |
| DRUG | JNJ-77242113 Matching Placebo | JNJ-77242113 matching placebo will be administered orally. |
| DRUG | Deucravacitinib | Deucravacitinib will be administered orally. |
| DRUG | Deucravacitinib Matching Placebo | Deucravacitinib matching placebo will be administered orally. |
Timeline
- Start date
- 2024-03-09
- Primary completion
- 2024-11-15
- Completion
- 2027-09-20
- First posted
- 2024-01-24
- Last updated
- 2026-03-12
Locations
128 sites across 11 countries: United States, Australia, Brazil, Canada, Germany, Hungary, Poland, Romania, South Korea, Spain, Taiwan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06220604. Inclusion in this directory is not an endorsement.